THRB and metabolic dysfunction-associated steatohepatitis: On 14th March 2024, the US Food and Drug Administration (FDA) granted approval to the first medication, resmetirom (an oral, liver-directed, thyroid hormone receptor beta–selective agonist) for metabolic dysfunction-associated steatohepatitis (MASH) [182].